Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | CPI-0610 |
Synonyms | |
Therapy Description |
CPI-0610 is a small molecule that binds to BET bromodomains and inhibits interaction with acetylated histones, resulting in regulation of BET-dependent gene expression and anti-tumor effects (PMID: 26815195, PMID: 31729905). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
CPI-0610 | CPI0610|pelabresib | BET Inhibitor (Pan) 32 | CPI-0610 is a small molecule that binds to BET bromodomains and inhibits interaction with acetylated histones, resulting in regulation of BET-dependent gene expression and anti-tumor effects (PMID: 26815195, PMID: 31729905). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT02157636 | Phase I | CPI-0610 | A Phase 1 Study Evaluating CPI-0610 in Patients With Previously Treated Multiple Myeloma | Completed | 0 | |
NCT02986919 | Phase II | CPI-0610 | Study of CPI-0610 in Patients With Malignant Peripheral Nerve Sheath Tumors | Withdrawn | USA | 0 |
NCT01949883 | Phase I | CPI-0610 | A Phase 1 Study Evaluating CPI-0610 in Patients With Progressive Lymphoma | Completed | 0 | |
NCT02158858 | Phase Ib/II | CPI-0610 + Ruxolitinib CPI-0610 | A Phase 2 Study of CPI-0610 With and Without Ruxolitinib in Patients With Myelofibrosis | Active, not recruiting | USA | POL | NLD | ITA | GBR | FRA | DEU | CAN | BEL | 0 |